Evidence map›Paper›PMID 39037469›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2024

Investigation of choroidal structure changes after intravitreal anti-VEGF therapy for retinal vein occlusion.

Erdem Dursun, Baki Derhem, Seval Çobanoğlu, Tevfik Oğurel

Abstract read
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Erdem DursunFaculty of Medicine, Ophthalmology Department, Kırıkkale University, Seyrantepe Mh. Asude Kent Sitesi C Blok no:22 Yahsihan, Kırıkkale, Turkey. erdem.drsn@gmail.com.ORCID http://orcid.org/0000-0002-4320-9336
Baki DerhemFaculty of Medicine, Family Medicine Department, Kırıkkale University, Kırıkkale, Turkey.ORCID http://orcid.org/0000-0002-6989-9873
Seval ÇobanoğluFaculty of Medicine, Ophthalmology Department, Kırıkkale University, Seyrantepe Mh. Asude Kent Sitesi C Blok no:22 Yahsihan, Kırıkkale, Turkey.ORCID http://orcid.org/0000-0002-6349-7136
Tevfik OğurelFaculty of Medicine, Ophthalmology Department, Kırıkkale University, Seyrantepe Mh. Asude Kent Sitesi C Blok no:22 Yahsihan, Kırıkkale, Turkey.ORCID http://orcid.org/0000-0003-0658-2286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to investigate the effect of retinal vein occlusion (RVO) on the posterior segment structures of the eye and its changes with intravitreal anti-Vascular Endothelial Growth Factor (VEGF) treatment.

methodsThis prospective longitudinal study included 29 eyes of 29 patients with RVO (17 males and 12 females) followed for 6 months. The best corrected visual acuity (BCVA), macula, choroid ticknesses and choroidal vascularity index (CVI) obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the first injection. Results were compared with fellow eyes (non-affected eyes) and age- and sex-matched controls.

resultsBCVA increased significantly in the 6th month, more in the first month of injection (p < 0.05 for each). Central macular tickness, subfoveal choroid tickness, stromal and total area of choroid decreased significantly after injection (p < 0.05 for each). CVI values increased significantly, especially in the 1st month after injection (p < 0.05 for each). In eyes with Branch RVO, there was a significant decrease in the macular thickness of the occlusive areas with treatment, while there was no statistically significant change in the non-occlusive macular thickness.

conclusionObservation of changes in choroidal structure may be useful to assess the activity of RVO and predict the efficacy of anti-VEGF therapy.

Indexed as

Angiogenesis InhibitorsChoroidFluorescein AngiographyIntravitreal InjectionsRanibizumabRetinal Vein OcclusionTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityAgedBevacizumabFemaleFollow-Up StudiesFundus OculiHumansMacula LuteaAngiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor ACentral macular thicknessChoroid thicknessChoroid vascularity indexRetinal vein occlusionVascular endothelial growth factor

Identifiers

PMID39037469
PMCPMC11608387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.